Updated:
Sigyn Therapeutics, Inc.
Sigyn Therapeutics, Inc. is a biomedical company developing the ChemoPure blood purification platform for chemotherapy removal.
Sigyn Therapeutics, Inc.
Sigyn Therapeutics, Inc. was founded as a corporate entity but has not publicly disclosed its founding year or founding principals. The company's primary asset is the ChemoPure platform, a blood purification system intended to reduce side effects of chemotherapy by removing residual drugs from circulation post-treatment. As of public records, the firm has not reported revenue or commercial operations, and its status as an investment vehicle is unconfirmed. The company does not appear to manage capital or deploy assets in sectors, stages, or geographies typical of family offices or asset managers. No named portfolio companies, deals, or co-investors have been disclosed. The geographic footprint is unknown, and no team size or professional headcount has been published. No recent operational events within the last 24 months have been identified. The firm has not announced fundraising, partnerships, or clinical milestones since its public availability. Adjacent vehicles such as foundations or operating companies are not disclosed. Structural differentiator: Sigyn Therapeutics represents a single-asset therapeutic developer with no disclosed investment mandate or capital management activity. This distinguishes it from conventional family offices or allocators, which typically operate diversified portfolios. The entity's purpose appears to be drug development rather than wealth management or investment.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Is Sigyn Therapeutics a family office or investment firm?
No. Sigyn Therapeutics, Inc. is a development-stage biomedical technology company focused on creating the ChemoPure blood purification therapy platform. Public records do not indicate it operates as a family office, asset manager, or institutional allocator.
What is ChemoPure?
ChemoPure is a blood purification therapy platform designed to remove chemotherapy agents from the bloodstream after cancer treatment. The technology is still in development and has not reached commercial deployment (per public record).
Does Sigyn Therapeutics manage capital for external investors?
No evidence suggests the firm manages capital for external clients or allocators. Its activities center on therapeutic development rather than investment management.
Who leads Sigyn Therapeutics?
Public records do not identify named principals or leadership for the entity. No CEO, CIO, or managing director has been disclosed in accessible sources.
What is the firm's investment strategy or asset class focus?
The firm has not disclosed an investment strategy or asset class focus. It does not report allocations to private equity, venture capital, hedge funds, real estate, or any other typical family office asset classes.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: